Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial

Fineline Cube Apr 29, 2026
Company Drug

Insilico Medicine Secures Chinese Clinical Clearance for AI-Discovered Rentosertib Inhalation in Pulmonary Fibrosis

Fineline Cube Apr 29, 2026
Company Drug

Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer

Fineline Cube Aug 17, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Deals

Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform

Fineline Cube Aug 17, 2023

US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...

Company Digital

JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report

Fineline Cube Aug 17, 2023

JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...

Company

Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law

Fineline Cube Aug 17, 2023

Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...

Company Drug

Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis

Fineline Cube Aug 16, 2023

China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...

Company

Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom

Fineline Cube Aug 16, 2023

Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...

Company

Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment

Fineline Cube Aug 16, 2023

Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...

Company Drug

Yingli Pharma’s Linperlislib Receives Priority Review Status for Lymphoma Treatments

Fineline Cube Aug 16, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US...

Company

Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending

Fineline Cube Aug 16, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...

Company Deals

Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal

Fineline Cube Aug 16, 2023

Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...

Company Drug

Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept

Fineline Cube Aug 16, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...

Company Deals

Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies

Fineline Cube Aug 16, 2023

Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development

Fineline Cube Aug 16, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...

Company Drug

YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment

Fineline Cube Aug 16, 2023

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...

Company Drug

Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam

Fineline Cube Aug 16, 2023

China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...

Company

CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones

Fineline Cube Aug 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business...

Company Deals

HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research

Fineline Cube Aug 15, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...

Company Drug

Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication

Fineline Cube Aug 15, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Suzhou Leadsynbio Secures Series D Funding to Boost R&D and Market Presence

Fineline Cube Aug 15, 2023

Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy

Fineline Cube Aug 15, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...

Posts pagination

1 … 481 482 483 … 659

Recent updates

  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
  • Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion
  • Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement
  • Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets
  • Changchun High & New Tech’s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed

Company

Astellas Reports Strong FY2025 Results with 12% Revenue Growth Driven by Oncology Portfolio Expansion

Company

Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement

Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.